Last updated: April 28, 2026
What is Cardene in 0.86% Sodium Chloride in plastic container?
“Cardene” is the brand name for nicardipine, a dihydropyridine calcium-channel blocker, formulated for intravenous infusion. The specified presentation is Cardene in 0.86% Sodium Chloride in plastic container, meaning nicardipine is supplied in a 0.86% saline carrier solution in a plastic container (ready-to-use IV administration configuration).
Which clinical-trial signals matter for this specific IV formulation?
For decision-grade conclusions on this exact marketed configuration (nicardipine in 0.86% sodium chloride in plastic container), the key question is whether there are current, ongoing, or recently completed clinical trials that explicitly evaluate:
- Nicardipine IV versus another comparator in labeled indications (hypertension/ICU settings), and/or
- This formulation configuration (0.86% saline in plastic container) in outcomes or pharmacokinetics.
The available public clinical-trial record for nicardipine is dominated by older studies and broad nicardipine IV evidence rather than trials that isolate the container and exact saline strength as a primary endpoint. Public registries typically index trials by active ingredient, route, and protocol, not by packaging/container. As a result, formulation-specific clinical differentiation generally does not appear as a distinct modern clinical-trial category in registry entries for nicardipine IV.
Practical read-across for R&D and investment: If there is no ongoing trial that distinguishes “0.86% saline in plastic container” as a studied variable, then the risk profile for this configuration is usually governed by:
- Nicardipine clinical evidence (older but still label-consistent),
- manufacturing and stability/compatibility standards for IV solutions, and
- regulatory/quality lifecycle for formulation and packaging.
What is the current clinical use landscape for nicardipine IV?
Across hospital markets, nicardipine IV is used in settings where clinicians need rapid, titratable blood-pressure control, commonly including:
- Hypertensive emergencies (acute severe hypertension with end-organ concerns),
- Post-operative or perioperative blood-pressure management in controlled settings,
- Neurosurgical and neurologic ICU workflows (where titratability and controllability are valued).
The clinical value proposition in practice is short-acting IV titration rather than long-duration oral maintenance. That use pattern tends to keep demand tied to:
- ICU bed flow,
- protocol standardization in hospital formularies,
- and procurement cycles for IV antihypertensives.
What does market demand for nicardipine IV look like (and what drives it)?
For “Cardene in 0.86% sodium chloride in plastic container,” the market is best understood as hospital acute-care IV demand with procurement driven by three forces:
1) Hospital procurement cycles and formulary inclusion
- Nicardipine’s inclusion in hospital formularies typically depends on comparative efficacy, safety, nursing/ICU workflow fit, and procurement economics versus alternatives like clevidipine, labetalol, nitroprusside, and other IV calcium-channel blockers or beta-blockers.
- IV antihypertensive use is sensitive to protocol adoption and availability during supply disruptions.
2) Competitive class substitution risk (IV CCB and other IV antihypertensives)
- In hospitals that stock multiple IV agents, clinicians may switch based on institutional preference, side-effect tolerability, and drug availability.
- If competitors have better ease-of-use, container formats, or pricing, substitution can compress net revenue even if overall ICU hypertension treatment volumes remain stable.
3) Availability, manufacturing continuity, and packaging requirements
For a specific “plastic container” saline configuration, supply stability matters. Any manufacturing interruption for this packaging configuration can:
- trigger temporary substitution,
- create longer-term switching if stockouts lead to formulary updates,
- or force channel buyers to rebalance inventory.
How does the regulatory and lifecycle structure impact this product class?
For branded nicardipine IV, the commercial life is shaped by:
- patent term and exclusivity (original compound and formulation-specific protection, if any),
- generic entry and whether generics match the same container/solution specifications,
- and any remedial approvals for manufacturing and stability/compatibility.
In practice, once the compound is no longer under effective exclusivity, branded pricing erodes unless:
- the branded entity retains channel relationships and treatment protocol stickiness, or
- generics enter at parity that reduces total spend rather than displacing volume.
Market projection: where growth or decline typically comes from
Without formulation-specific unit sales data in the public domain, projection must be built from healthcare system drivers that affect IV antihypertensive dispensing volume:
Demand drivers (upside)
- Growth in hospital utilization for acute-care pathways that require IV titration.
- Standardization of rapid titratable IV BP agents in protocols for acute hypertension and neurocritical care workflows.
- Periodic supply gaps in any competitor that increase volume captured by available agents.
Headwinds (downside)
- Generic penetration and aggressive pricing pressure in hospital channels.
- Substitution to other IV agents (notably IV alternatives with strong protocol adoption).
- Procurement push for cost containment, which can reduce branded net price even when volume holds.
Scenario-based projection framework (commercial planning view)
A practical projection for “Cardene in 0.86% sodium chloride in plastic container” is typically managed using three scenarios:
| Scenario |
Volume trend |
Net price trend |
Revenue trend |
Key condition |
| Base |
Stable to slight decline |
Declining |
Flat to down |
Generic pressure offsets protocol retention |
| Upside |
Flat to slight growth |
Stable to mildly down |
Slight growth |
Competitor supply constraints or protocol gains |
| Downside |
Decline |
Sharp down |
Meaningful decline |
Formularies switch and net pricing compresses |
This framework aligns with how IV hospital-branded products usually perform post-generic entry: net price moves first, volume follows with formulary dynamics.
What competitive benchmarks matter most?
For a decision-grade outlook, the benchmark set that most affects nicardipine IV branded performance is:
- IV clevidipine (another IV CCB with acute BP titration use),
- IV labetalol and nitroprusside (alternative acute BP agents),
- local and regional generic nicardipine IV offerings and their packaging compatibility.
The packaging “plastic container” is relevant because:
- nursing acceptance and priming compatibility influence day-to-day usage,
- procurement favors supply continuity and chain-of-custody reliability,
- and substitution decisions often happen at the product configuration level.
What is the actionable watchlist for clinical and market developments?
Because “0.86% saline in plastic container” is not typically a standalone trial endpoint, the watchlist becomes:
- Any new clinical publication or trial that changes guideline positioning for nicardipine IV in hypertensive emergencies or neurocritical care workflows.
- Regulatory actions tied to this specific presentation (manufacturing changes, labeling updates, shortages, discontinuations).
- Formulary and procurement signals: switching patterns in major hospital groups.
- Supply chain events: whether competitor agents experience shortages or allocation, which can temporarily shift volume share.
Key Takeaways
- Cardene in 0.86% sodium chloride in plastic container is an IV nicardipine product configuration aimed at rapid, titratable acute blood-pressure control in hospital settings.
- Public clinical trial activity for nicardipine generally does not isolate this exact formulation and container as a distinct modern clinical endpoint category; current clinical value is driven by established nicardipine IV evidence and protocol inclusion rather than ongoing formulation-specific trials.
- Commercial performance should be projected using hospital IV demand dynamics and substitution/generic pricing pressure, with revenue typically determined by net price compression first, then volume via formulary switching.
- A scenario approach (Base/Upside/Downside) is the most decision-useful projection method for this branded IV presentation given the lack of formulation-specific public trial differentiation.
FAQs
-
Is there a modern clinical-trial readout specifically for “0.86% sodium chloride in plastic container”?
Public trial records for nicardipine IV typically do not isolate packaging/container configuration as a primary studied variable.
-
What indications drive nicardipine IV demand most in hospitals?
Acute, titratable blood-pressure management in hypertensive emergencies and other acute-care settings where rapid control is required, including ICU/neurocritical workflows.
-
What most strongly affects branded sales of Cardene in this configuration?
Net pricing pressure from generics and substitution among IV antihypertensives, mediated by hospital formulary and procurement cycles.
-
Why does “plastic container” matter commercially?
Packaging affects day-to-day usability, supply continuity perception, and substitution decisions at the product-configuration level during procure-to-admin workflows.
-
What should be monitored for near-term market movement?
Competitor supply disruptions, hospital group formulary changes, and any regulatory or manufacturing actions impacting this specific presentation.
References
[1] U.S. FDA. Drug Approval Reports and product labeling for nicardipine hydrochloride (Cardene). https://www.accessdata.fda.gov/
